Ibrutix 140 MG (Ibrutinib)

Basic Product Information of Ibrutix (Ibrutinib) 140mg

How Ibrutix (Ibrutinib) Works

Ibrutix contains Ibrutinib, a first-in-class, potent, orally administered inhibitor of Bruton’s Tyrosine Kinase (BTK). BTK is a signalling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways, and plays a central role in the survival, proliferation, trafficking, and adhesion of malignant B cells in blood cancers such as CLL, MCL, WM, and MZL.

Ibrutinib forms a covalent bond with a cysteine residue in the BTK active site, irreversibly inhibiting its enzymatic activity. By blocking downstream B-cell receptor signalling, Ibrutix disrupts the survival and spread of malignant B cells, driving them towards programmed cell death (apoptosis) while also inhibiting cell migration and adhesion within the tumour microenvironment. In chronic GVHD, Ibrutinib is also thought to act partly through inhibition of a related kinase, ITK.

Because of this precise, mechanism-driven action, Ibrutix is classified as a targeted therapy rather than conventional chemotherapy. It is administered as a once-daily oral capsule, offering a convenient outpatient treatment option for patients with these blood cancers and cGVHD.

Indications for Ibrutix (Ibrutinib)

Ibrutix (Ibrutinib) is indicated for the following conditions:

Benefits of Ibrutix (Ibrutinib) 140mg

How to Take Ibrutix (Ibrutinib)

Monitoring and Dosage Adjustments

Regular monitoring is essential throughout Ibrutix treatment. Your haemato-oncologist will monitor complete blood counts monthly for cytopenias, assess for signs of bleeding or bruising, and monitor for cardiac arrhythmias such as palpitations, dizziness, or shortness of breath, with ECG evaluation where indicated. Monitoring also includes periodic blood pressure checks, liver function tests, and vigilance for signs of infection and, in high tumour burden patients, tumour lysis syndrome. Treatment may be interrupted or dose-reduced to manage toxicity. Report any unusual bleeding, bruising, chest palpitations, breathlessness, or fever to your doctor immediately.

Drug Interactions and Important Information

Avoid concomitant use of Ibrutix with strong CYP3A4 inhibitors (such as ketoconazole, itraconazole, clarithromycin, and ritonavir) where possible, as these significantly increase Ibrutinib plasma exposure. Avoid concomitant use with strong CYP3A4 inducers (such as rifampicin, carbamazepine, and phenytoin), as these reduce Ibrutinib efficacy.

Use with caution alongside anticoagulants and antiplatelet agents (such as warfarin), as combined use may increase the risk of bleeding; supplements such as fish oil and vitamin E preparations should also be used cautiously. Avoid grapefruit, grapefruit juice, Seville oranges, and Seville orange juice during treatment. Women of childbearing potential should use effective contraception during treatment and for a period after the final dose. Always inform your physician of all medications, supplements, and herbal products you are currently taking before starting Ibrutix.

Side Effects and Precautions

Who Should Use Ibrutix (Ibrutinib)?

Ibrutix is suitable for adult patients diagnosed with Mantle Cell Lymphoma after at least one prior therapy, Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma including 17p deletion, Waldenstrom’s Macroglobulinemia, Marginal Zone Lymphoma after prior anti-CD20-based therapy, or chronic Graft-Versus-Host Disease after failure of other systemic therapy. It is prescribed by haemato-oncologists and transplant specialists experienced in managing B-cell malignancies and post-transplant complications. A thorough medical assessment including cardiac evaluation, baseline blood counts, and liver function is required before initiating treatment.

Manufacturer: Beacon Pharmaceuticals Ltd.

Beacon Pharmaceuticals Ltd. is a leading pharmaceutical manufacturer based in Mymensingh, Bangladesh, and the number one oncology and specialty medicine company in the country. Beacon is the first company in Bangladesh to export cancer drugs and currently exports to Asia, Africa, Europe, and Latin America. With a broad portfolio of oncology and specialty products, Beacon operates under strict WHO-GMP, cGMP, and ISO-certified standards. Ibrutix is one of Beacon’s globally recognised specialty products, offering an affordable and bioequivalent alternative to Imbruvica at a fraction of the cost.

Global Supplier: Mediaid Pharmacy with Worldwide Shipping

Mediaid Pharmacy is a trusted global supplier of specialty and oncology medications. We ensure Ibrutix (Ibrutinib) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.

Why Choose Ibrutix (Ibrutinib) from Mediaid Pharmacy?

Ibrutix represents a major advancement in the targeted treatment of B-cell blood cancers. As the generic equivalent of Imbruvica, it delivers the same active ingredient, Ibrutinib, with the same proven BTK-inhibition mechanism at a dramatically more affordable price. Manufactured by the internationally trusted Beacon Pharmaceuticals Ltd. under WHO-GMP and cGMP standards, and distributed globally by Mediaid Pharmacy, Ibrutix gives patients worldwide access to high-quality targeted therapy for CLL, MCL, WM, MZL, and cGVHD without the financial burden of brand-name alternatives. For patients and physicians seeking a proven, affordable, and accessible Ibrutinib option with worldwide delivery, Ibrutix from Mediaid Pharmacy is the trusted choice.

Frequently Asked Questions About Ibrutix (Ibrutinib)